The Ken

1 week ago | the-ken.com | Rohin Dharmakumar

The coffee culture in India has come far today. But has it reached the point where daily commuters grab their cup of joe from their favourite cafe on their way to work? Or do they get it delivered in minutes? Or is the cafe only a destination for meetings? The cafe ideally serves all three use cases. But the bigger reason has more to do with what we as Indians associate with cafes when we walk into a cafe. Some answer lies in the split between food and beverages in India.

1 week ago | the-ken.com | Arundhati Ramanathan

A weekly newsletter about how finance is getting supercharged by tech in India, and how you can make money work for you. Subscribe here Good morning [%first_name |Dear Reader%], You are reading our subscriber-only newsletter Ka-Ching!—a weekly commentary on fintech and personal finance Enter your email address to receive a daily curation of our latest newsletters, stories, and podcasts.

1 week ago | the-ken.com | Aakriti Bhalla

Aakriti is a business reporter spotting trends in consumerism. She works at the intersection of the food & beverages, consumer and retail industry. Fifteen years ago, the Tatas rolled out the red carpet for Zara. They stood behind, learnt the ropes, launched a new brand, and quietly began outperforming the Spanish retailer. And now, that bond is starting to crack.

1 week ago | the-ken.com | Snigdha Sharma

India had as estimated 101 million diabetics in 2023, with another 136 million people in pre-diabetic state. Among them, 11 million people are on insulin therapy. It’s a market worth nearly Rs 5,000 crore with Novo Nordisk as the leader, controlling 60%. Two other MNCs—Sanofi and Eli Lilly—control another 25%. All three companies are phasing out their insulin products in the country.

1 week ago | the-ken.com | Seema Singh

Good morning [%first_name |Dear Reader%], When big ships turn, they displace a lot of water. And the Danish giant Novo Nordisk is making a sharp turn. It's phasing out insulin, the life-saving drug that has been in the market for over 40 years, to make way for newer, better, and more expensive products. In India, some 11 million diabetics are on insulin, and Novo commands 60% of the nearly Rs 5,000 crore market.